Merck KGaA Rebif Faces Irreversible Decline; Avelumab Update Seen Soon
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the German multinational’s best-selling MS product sharply declined in the second quarter, but higher investment is likely to boost its research pipeline of early- and late-stage products.